Inhibikase Therapeutics, Inc. - Common Stock — 재무제표 (NASDAQ:IKT) | MetaTrader

전체 차트 열기 Full chart

뉴스

BofA 증권, Inhibikase에 ’매수’ 등급 제시

BofA Securities initiates coverage on Inhibikase stock with Buy rating

제퍼리스, 이니비카제에 ’매수’ 등급 재확인...FDA 승인 가속화

Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path

H.C. Wainwright, Inhibikase에 ’매수’ 의견 제시

H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating

Monday’s Insider Activity: Top Executives Trade Shares at Tech Giants

Why Intuit Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Gap (NYSE:GAP), Elastic (NYSE:ESTC)

Inhibikase Therapeutics, 1억 달러 규모 공모 발행 가격 결정

Inhibikase Therapeutics prices $100 million public offering

Inhibikase Therapeutics, 공모 발표 후 주가 하락

Inhibikase Therapeutics stock falls after announcing public offering